Lyell Immunopharma, Inc. (LYEL)
| Market Cap | 418.12M +201.2% |
| Revenue (ttm) | 31,000 -52.3% |
| Net Income | -246.41M |
| EPS | -13.06 |
| Shares Out | 23.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 107,622 |
| Open | 18.56 |
| Previous Close | 19.02 |
| Day's Range | 17.43 - 18.73 |
| 52-Week Range | 7.65 - 45.00 |
| Beta | -0.06 |
| Analysts | Strong Buy |
| Price Target | 30.60 (+70.76%) |
| Earnings Date | May 6, 2026 |
About LYEL
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual‑targeting CD19/CD20 CAR T‑cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy random... [Read more]
Financial Performance
In 2025, Lyell Immunopharma's revenue was $36,000, a decrease of -40.98% compared to the previous year's $61,000. Losses were -$274.45 million, -19.98% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for LYEL stock is "Strong Buy." The 12-month stock price target is $30.6, which is an increase of 70.76% from the latest price.
News
Lyell Immunopharma Announces Participation in May Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (...
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027...
Lyell Immunopharma initiated with an Outperform at Baird on ronde-cel potential
As previously reported, Baird initiated coverage of Lyell Immunopharma (LYEL) with an Outperform rating and $49 price target Lyell’s pipeline is headlined by ronde-cel, for which a pair of pivotal…
Lyell Immunopharma initiated with an Outperform at Baird
Baird initiated coverage of Lyell Immunopharma (LYEL) with an Outperform rating and $49 price target
Lyell Immunopharma Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is advancing next-generation CAR T-cell therapies, with ronde-cel showing high response rates and a favorable safety profile in pivotal trials. Manufacturing is fully in-house, and commercial launch is targeted for next year. LYL273 for solid tumors is also progressing, with promising early data and upcoming disclosures.
Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst
Lyell Immunopharma stock was down despite praise from a top Wall Street analyst on Friday.
Lyell Immunopharma initiated with a Buy at Needham
Needham initiated coverage of Lyell Immunopharma (LYEL) with a Buy rating and $44 price target The firm says the company’s ronde-cel is in the “pole position” for second-line diffuse large…
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...
Lyell Immunopharma price target raised to $39 from $32 at Lucid Capital
Lucid Capital analyst Christopher Liu raised the firm’s price target on Lyell Immunopharma (LYEL) to $39 from $32 and keeps a Buy rating on the shares following the fiscal 2025…
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...
Lyell Immunopharma Transcript: The Citizens Life Sciences Conference 2026
Multiple pivotal trials are advancing for next-generation CAR T-cell therapies in lymphoma and colorectal cancer, with strong early efficacy and safety data. Major data updates are expected in H2, and financial resources are secured for continued development.
Lyell Immunopharma Transcript: Leerink Global Healthcare Conference 2026
Key updates include a new CFO hire, a $50M financing milestone, and strong clinical progress for the dual-targeted ronde-cel CAR T-cell therapy, which shows high response rates and a favorable safety profile. The company is also advancing a novel GCC CAR T-cell program for solid tumors, with promising early data and upcoming readouts.
Lyell Immunopharma appoints Smital Shah as CFBO
Lyell Immunopharma (LYEL) closed the sale of an additional $50M of shares of its common stock to investors from its July 2025 equity private placement of up to $100M, following…
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...
Lyell Immunopharma initiated with an Outperform at Citizens
Citizens initiated coverage of Lyell Immunopharma (LYEL) with an Outperform rating and $34 price target Ronde-Cel, the company’s lead dual-targeting CD19/CD20 CAR T-cell therapy, has demonstrated “pro...
Lyell Immunopharma Transcript: TD Cowen 46th Annual Health Care Conference
Significant clinical progress was highlighted for dual-targeting CAR T-cell therapies in lymphoma and colorectal cancer, with pivotal trials underway and promising early efficacy and safety data. Scalable manufacturing and a strong cash position support upcoming milestones through 2027.
Lyell Immunopharma Announces Participation in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR)...
Lyell Immunopharma initiates patient dosing in PiNACLE-H2H Phase 3 trial
Lyell Immunopharma (LYEL) announced that the first patient has been dosed in the PiNACLE – H2H Phase 3 trial evaluating rondecabtagene autoleucel compared to lisocabtagene maraleucel or axicabtagene c...
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR)...
Lyell Immunopharma trading resumes
12:14 EST Lyell Immunopharma (LYEL) trading resumes
Lyell Immunopharma trading halted, volatility trading pause
12:04 EST Lyell Immunopharma (LYEL) trading halted, volatility trading pause
Lyell Immunopharma upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Lyell Immunopharma (LYEL) to Buy from Neutral with a price target of $45, up from $20. The firm has “increased conviction” following the company’s recent data and…
Lyell Immunopharma Transcript: Study Update
Ronde-cel demonstrated high response and durable remission rates in high-risk large B-cell lymphoma patients, with a favorable safety profile and strong translational data supporting its mechanism. LYL273 showed promising efficacy in metastatic colorectal cancer, with manageable safety and innovative design.
Lyell Immunopharma announces new data from trial of rondecabtagene autoleucel
Lyell Immunopharma (LYEL) announced new clinical and translational data from the ongoing clinical trial of rondecabtagene autoleucel in patients with large B-cell lymphoma, LBCL, which were presented ...
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR)...